✦ LIBER ✦

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

✍ Scribed by Mikael Simons; Frank Schwärzler; Dieter Lütjohann; Klaus Von Bergmann; Konrad Beyreuther; Johannes Dichgans; Henning Wormstall; Tobias Hartmann; Jörg B. Schulz

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 89 KB
Volume: 52
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.10292

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Interferon-α does not improve outcome at

Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial

✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal

Imipramine and diet counseling with psyc

Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: A randomized, placebo-controlled double-blind study

✍ Laederach-Hofmann, Kurt ;Graf, Claudio ;Horber, Fritz ;Lippuner, Kurt ;Lederer, 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 188 KB 👁 2 views

Objective: This study with 31 obese binge eaters (body mass index [BMI] 39.5 ± 8.6 kg/m 2 [SD]) was designed to assess whether diet counseling with psychological support and imipramine or placebo has an effect on the frequency of binge eating, body weight, and depression during an 8-week treatment p

Comparison of the effect of rofecoxib (a

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

✍ Christopher Hawkey; Loren Laine; Thomas Simon; Andre Beaulieu; Jose Maldonado-Co 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

No benefit of long-term ciprofloxacin tr

No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study

✍ Joachim Sieper; Claas Fendler; Sigrid Laitko; Helmut Sörensen; Christel Gripenbe 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre